← Oncology Approval Tracker

FDA DECISION ·

Pepaxto

melphalan flufenamide with dexamethasone · Oncopeptides

Accelerated approvalNew therapyMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on Feb 23, 2024

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with relapsed or refractory multiple myeloma after four or more prior lines and resistance to a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 antibody. FDA withdrew approval on February 23, 2024.

LAMPGEN ANALYSIS

Why it matters

The historical authorization defined a heavily treated, triple-class-refractory population. The later FDA withdrawal changed its regulatory status.

What research teams should watch

Preserve individual drug class exposure and distinguish the historical decision from current treatment options.

PRIMARY RECORDS

Sources